Impact of urinary selective antibiogram in primary care / Impacto do antibiograma seletivo nas uroculturas em cuidados primários

ABSTRACT INTRODUCTION: Selective reporting of antibiotic susceptibility test results (selective antibiogram), is increasingly recognized as one of the key strategies of antibiotic stewardship programs. The objective of this study is to determine the impact of selective susceptibility reporting on ciprofloxacin utilization and Escherichia coli susceptibility to ciprofloxacin in the outpatient setting. MATERIAL AND METHODS: A selective reporting policy was created and implemented in 2011. The policy involves the non-reporting of ciprofloxacin susceptibility to Enterobacteriaceae isolated in a urine sample when there was susceptibility to other agents with narrow spectrum. The outcomes evaluated were outpatient ciprofloxacin utilization and E. coli susceptibility to ciprofloxacin between January 2011 and December 2018 RESULTS: Between 2011 and 2018 we detected an increased susceptibility rate of E. coli to ciprofloxacin from 79% to 87% (p < 0.001) and a decreased incidence rate of E. coli resistant to ciprofloxacin from 2.52 to 0.87 (p < 0.001). The ciprofloxacin dropped from 0.75 defined daily doses (DHD) to 0.36 DHD and there was a compensatory increase in nitrofurantoin and fosfomycin utilization. DISCUSSION: Our study showed that selective reporting can influence prescribing practice in a community level and encourages clinicians to select more narrow-spectrum and cost-effective antimicrobial agents in UTIs. CONCLUSION: Our results suggest that selective antibiogram should be considered an effective prevention strategy to reduce targeted antimicrobial utilization.

RESUMEN INTRODUCCIÓN: La notificación selectiva de resultados de la prueba de susceptibilidad bacteriana (antibiograma selectivo) es conocida como una de las estrategias clave de los programas de optimización de antimicrobianos. El objetivo de este estudio fue determinar el impacto del antibiograma selectivo en el consumo de ciprofloxacino y la sensibilidad de la bacteria Escherichia coli al ciprofloxacino en la atención básica. MATERIAL Y MÉTODOS: La política de informe selectivo fue creada e implementada en 2011 e incluyó la no trasmisión, en el antibiograma, de sensibilidad de Enterobacteriaceae al ciprofloxacino en muestras urinarias cuando había sensibilidad a otros agentes de espectro reducido. Los desenlaces evaluados fueron el consumo de ciprofloxacino y la evolución de sensibilidad de E. coli al ciprofloxacino entre enero de 2011 y diciembre de 2018. RESULTADOS En esse período, se detectó un aumento en la tasa de sensibilidad de E. coli al ciprofloxacino, del 79% al 87% (p < 0,001). La tasa de incidencia de E. coli resistente al ciprofloxacino descendió de 2,52 a 0,87 (p < 0,001). El consumo de ciprofloxacino tuvo un descenso de 0,75 doses por mil habitantes día (DHD) a 0,36 DHD. Al mismo tiempo, un aumento compensatorio se observó en el consumo de nitrofurantoína y fosfomicina. DISCUSIÓN: Nuestro estudio demostró que el uso del antibiograma selectivo influyó en la práctica de prescripción de antimicrobianos y animó a los médicos generales a elegir antimicrobianos de espectro más reducido y con mejor relación de costo-beneficio. CONCLUSIÓN: Nuestros resultados sugieren que la utilización de antibiogramas selectivos debe ser considerada una estrategia efectiva en la reducción del consumo de determinados antimicrobianos.

RESUMO INTRODUÇÃO: A notificação seletiva dos resultados do teste de suscetibilidade aos antimicrobianos (antibiograma seletivo) é conhecida como uma das estratégias-chave dos programas de apoio à prescrição de antibióticos. O objetivo deste estudo foi determinar o impacto do antibiograma seletivo no consumo de ciprofloxacino e a suscetibilidade da bactéria Escherichia coli ao ciprofloxacino nos cuidados primários. MATERIAL E MÉTODOS: A política de notificação seletiva foi criada e implementada em 2011 e envolveu a não transmissão, no antibiograma, da suscetibilidade da família Enterobacteriaceae ao ciprofloxacino em amostras urinárias quando existia suscetibilidade a outros agentes com menor espectro. Os desfechos avaliados foram consumo de ciprofloxacino e evolução da suscetibilidade de E. coli ao ciprofloxacino entre janeiro de 2011 e dezembro de 2018. RESULTADOS: Nesse período, um aumento foi detectado na taxa de suscetibilidade de E. coli ao ciprofloxacino, de 79% a 87% (p < 0,001). A taxa de incidência de E. coli resistente ao ciprofloxacino diminuiu de 2,52 para 0,87 (p < 0,001). O consumo de ciprofloxacino teve uma queda de 0,75 doses diárias definidas (DHD) para 0,36 DHD. Simultaneamente, um aumento compensatório foi observado no consumo de nitrofurantoína e fosfomicina. DISCUSSÃO: Nosso estudo demonstrou que a utilização do antibiograma seletivo influenciou a prática de prescrição dos antimicrobianos e incentivou os clínicos gerais a selecionar antimicrobianos de espectro de ação mais reduzido e com melhor relação custo-benefício. CONCLUSÃO: Nossos resultados sugerem que a utilização de antibiogramas seletivos deve ser considerada uma estratégia eficaz na redução do consumo de determinados antimicrobianos.

Actualización en la prescripción de fluoroquinolonas / Update on the prescription of fluoroquinolones

Resumen: Las quinolonas o fluoroquinolonas son un grupo de antibióticos frecuentemente prescritos y de amplio espectro que actúan inhibiendo a las enzimas encargadas de la replicación, transcripción, reparación y recombinación del ADN bacteriano. El objetivo de este artículo es presentar una revisión sistemática de los antecedentes, farmacocinética y actividad microbiológica de las tres fluoroquinolonas más representativas en nuestro medio (ciprofloxacino, levofloxacino y moxifloxacino) en sus tres indicaciones actualmente autorizadas: infecciones de vías respiratorias inferiores, de vías urinarias, de piel y tejidos blandos.

Abstract: Quinolones or fluoroquinolones are a group of commonly prescribed and broad-spectrum antibiotics drugs that act by inhibiting the enzymes responsible for the bacterial DNA replication, transcription, repair and recombination. The aim of this article is to present a systematic review of the three most representative fluoroquinolones in our country (ciprofloxacin, levofloxacin and moxifloxacin) in their three authorized indications: lower respiratory tract infections, urinary tract infections, skin and soft tissues infections.

Prescripción de ciprofloxacino por vía parenteral en pacientes ingresados en los servicios de Medicina Interna y Caumatología de un hospital general / Parenteral prescription of ciprofloxacin in patients admitted to the Internal Medicine and Caumatology services of a general hospital

Se realizó un estudio observacional descriptivo y transversal de 76 pacientes ingresados en los servicios de Medicina Interna y Caumatología del Hospital General Docente Dr Juan Bruno Zayas Alfonso de Santiago de Cuba durante el 2012, para evaluar los conocimientos, el desempeño y la satisfacción de 22 profesionales que prescribieron ciprofloxacino por vía parental. Los conocimientos y la satisfacción fueron evaluados a través de un examen de conocimientos y una encuesta de satisfacción, respectivamente; el desempeño, a partir de la información obtenida de las historias clínicas, relacionadas con tres criterios: individualización del tratamiento, esquema terapéutico y combinaciones medicamentosas. Para cada criterio se establecieron indicadores y estándares. Los prescriptores presentaron conocimientos adecuados sobre el medicamento en cuestión; sin embargo, el desempeño y la satisfacción de estos resultaron inadecuados. Se considera necesario realizar una intervención en aras de revertir las deficiencias identificadas y contribuir a elevar la calidad de la prescripción de medicamentos en ambos servicios de salud

A descriptive, cross-sectional and observational study of 76 patients admitted to the Internal Medicine and Caumatology services of Dr Juan Bruno Zayas Alfonso Teaching General Hospital was carried out in Santiago de Cuba during 2012, to evaluate the knowledge, performance and satisfaction of 22 professionals who prescribed parental ciprofloxacin. The knowledge and satisfaction were evaluated through a knowledge examination and a survey of satisfaction, respectively; the performance was evaluated, starting from the information obtained from the medical records, related to 3 criteria: individualization of the treatment, therapeutic schedule and medication combinations. For each opinion, indicators and standards were established. The prescribers presented appropriate knowledge on the specific medication; however, the performance and satisfaction of them were inadequate. It is necessary to carry out an intervention to revert the identified deficiencies and contribute to elevate the quality of the medications prescription in both health services

Caracterización clínica, epidemiológica y terapéutica de los pacientes con otitis externa maligna / Clinical, epidemiological and therapeutical characterization of patients with malignant external

Se realizó un estudio descriptivo de serie de casos, de 42 pacientes con otitis externa maligna, atendidos en el Servicio de Otorrinolaringología del Hospital Provincial Docente Clinicoquirúrgico Saturnino Lora de la provincia de Santiago de Cuba desde enero de 2002 hasta diciembre de 2014 y tratados básicamente con ciprofloxacina, a fin de caracterizarles clínica, epidemiológica y terapéuticamente, así como determinar su evolución clínica con el tratamiento indicado. También se incluyó un segundo grupo de 29 integrantes con la misma afección, quienes durante esos 12 años recibieron otros antibióticos y no la citada quinolona, tratados igualmente en dicho Servicio durante el período señalado. Entre los principales resultados sobresalió el predominio del grupo etario de 55-64 años (30,6 por ciento) en los que se utilizó ciprofloxacino y de 75 y más (74,8 por ciento) en los que se indicaron otros antimicrobianos; del tiempo de evolución de la diabetes mellitus de 0-10 años en 24 (57,1 por ciento) de quienes recibieron ciprofloxacino y en 14 (48,2 por ciento) de aquellos que no la consumieron y de la Pseudomonas aeruginosa como el germen más frecuentemente aislado. La evolución de los pacientes fue favorable, independientemente del tratamiento antimicrobiano prescrito, pero todos los tratados con ciprofloxacina egresaron en menos de 30 días mejorados o curados. Se concluyó que la edad avanzada favorece la aparición de la otitis externa maligna, sin importar el tiempo de evolución de la diabetes mellitus

A descriptive, serial cases study, of 42 patients with malignant external otitis was carried out. They were assisted in the Otolaryngology Service of Saturnino Lora Torres Teaching Clinical Surgical Provincial Hospital in Santiago de Cuba from January, 2002 to December, 2014 and treated basically with ciprofloxacin, in order to characterize them clinical, epidemiological and therapeutically, as well as to determine their clinical course with the suitable treatment. A second group of 29 members with the same disorder was also included who received other antibiotics during those 12 years, treated in this Service during that period. Among the main results there was a prevalence of the 55-64 years age group (30.6 percent) in which ciprofloxacin was used and over 75 years (74.8 percent) in which other antimicrobians were indicated; of the time in the diabetes mellitus course 0-10 years in 24 (57.1 percent) of those who received ciprofloxacin and in 14 (48.2 percent) of those that didn't consume it and of the Pseudomonas aeruginosa as the most frequently isolated germ. The patients had a favorable clinical course, no matter the antimicrobian prescribed treatment, but all the patients treated with ciprofloxacin got better or were cured and were discharged in less than 30 days. It was concluded that the advanced age favors the emergence of the malignant external otitis, no matter the time of the diabetes mellitus course

Evaluación de la resistencia a la erosión ácida de dos ionómeros de vidrio utilizados en la técnica restaurativa atraumática (TRA), modificados con un antibiótico / Evaluation of resistance to acid erosiion two glass ionomers used in the atraumatic restorative technique (art), modified with an antibiotic

En el presente estudio se evaluó la resistencia a la erosión ácida de dos ionómeros de vidrio de restauración, adicionados con ciprofloxacino al 2%, ya que la sinergia que tiene este con otras sustancias lo hace una sal adecuada para el estudio y puede ser utilizado en la técnica restaurativa atraumática.OBJETIVO: Evaluar la resistencia a la erosión ácida del ionómero de vidrio adicionado con ciprofloxacino al 2%, según los lineamientos de la norma 96 de la ADA.MATERIALES Y MÉTODOS: Se utilizaron dos marcas comerciales de ionómero de vidrio GC Gold Label 2® y KetacTM Molar Easymix®, conformando cuatro grupos: El grupo control que fueron los ionómeros de restauración convencionales, y el grupo de estudio al que se le adicionó ciprofloxacino al 2%. RESULTADOS: Fueron evaluados mediante el análisis de varianza ANOVA de una vía y se observó que en la comparación entre los dos grupos, no hubo diferencia estadísticamente significativa (p>0.005).CONCLUSIÓN: La adición del ciprofloxacino al 2% no altera la resistencia a la erosión ácida de los ionómeros de vidrio para restauración, y puede considerarse un material para ser utilizado en la técnica TRA en estudios posteriores. (AU)

In the present study the acid erosion resistance two glass ionomer restorative, ciprofloxacin added 2% was evaluated as having this synergy with other substances makes a suitable salt for the study and may be used in atraumatic restorative technique.OBJECTIVE: To evaluate the resistance to acid erosion glass ionomer added ciprofloxacin 2% to 2%, according to the guidelines of rule 96 of the ADA. MATERIALS AND METHODS: Two trademarks glass ionomer GC Gold Label 2® and KetacTM Molar Easymix® were used by forming two four groups: control group were conventional ionomer restoration, and the study group to which he was added 2% ciprofloxacin. Results: The results were evaluated by ANOVA one-way and was observed in the comparison between the two groups, there was no statistically significant difference (p>0.05). CONCLUSIONS: The addition of 2% ciprofloxacin does not alter the resistance to acid erosion of glass ionomer restoration, and may be considered a material that can to be used in the ART technique in subsequent studies. (AU)

Comparison of two otologic suspensions of ciprofloxacin 2 mg/mL and hydrocortisone 10 mg/mL in the treatment of otitis externa: a multicenter, double-blind, randomized study / Comparação de duas suspensões otológicas de ciprofloxacino 2 mg/mL e hidrocortisona 10 mg/mL no tratamento da otite externa: um estudo multicêntrico, duplo-cego e randomizado

This was Phase III multicenter, double-blind, randomized, comparative safety and efficacy study in parallel groups of subjects, assessing non-inferiority between two commercially available otologic suspensions containing ciprofloxacin 2mg/mL and hydrocortisone 10mg/mL (Otociriax and Cipro HC®) in the treatment of acute diffuse otitis externa. Following screening and informed consent, subjects were randomly allocated into two treatment groups: Group A (treated with Otociriax) and Group B (treated with Cipro HC®). Treatment regimen in both groups was three drops, twice daily for seven days. The primary study endpoint was otitis cure, defined as elimination of pain, edema, and otorrhea. The secondary study endpoint was presence of side effects. Efficacy assessments included presence and intensity of otitis externa manifestations. Safety assessments included vital signs and physical examination, as well as adverse event monitoring. Study data analysis was performed using GraphPad Prism 5.0...

Estudio biofarmacéutico comparativo de marcas comerciales de tabletas de ciprofloxacino disponibles en el mercado colombiano / A comparative biopharmaceutical study of brands of ciprofloxacin tablets available on the Colombian market

Objetivo: Determinar la equivalencia biofarmacéutica de marcas comerciales de Ciprofloxacino 500 mg disponibles en el mercado colombiano. Métodos: Se tomaron 12 productos comerciales de Ciprofloxacino tabletas 500 mg, adquiridos en droguerías y farmacias de cuatro de las principales ciudades del país, a los cuales se les realizaron los siguientes ensayos: Identificación del principio activo por HPLC, contenido de ingrediente activo, uniformidad de dosificación, pruebas de desintegración y disolución; además se compararon los perfiles de disolución de los productos frente a uno tomado como referencia. Los resultados se analizaron a fin de establecer diferencias estadísticamente significativas y posible intercambiabilidad entre los productos evaluados. Resultados: El análisis comparativo de los productos, permitió evidenciar marcadas diferencias en cuanto a la liberaciónin vitrodel principio activo, con uno de los productos incumpliendo este importante parámetro de calidad. Todos los productos evaluados cumplen con las especificaciones oficiales de identificación y valoración del principio activo, uniformidad de dosificación y tiempo de desintegración. En cuanto a la cinética de disolución se encontraron diferencias entre las formulaciones, con productos de deficiente Eficiencia de Disolución (ED) y que a pesar de cumplir con la especificación a Q30, se disuelven muy lentamente. Conclusiones: Once productos cumplen con todas las especificaciones establecidas en la USP-33/NF28. Los resultados de este trabajo constituyen un valioso aporte para en un futuro cercano y en función de las políticas nacionales, poder establecer bioequivalencia entre estos productos.

Objective: Determining the biopharmaceutical equivalency of 500 mg ciprofloxacin tablets available on the Colombian market (i.e. comparing different trademarks). Methods: Twelve commercial 500 mg ciprofloxacin tablets were obtained from drugstores and pharmacies in Colombia’s four major cities. They were submitted to the following assays: HPLC identification of active ingredients, active ingredient content, dose uniformity, disintegration and dissolution tests and comparing the products’ dissolution profiles to that of the innovator. The results were analyzed to establish statistically significant differences and possible inter-changeability between the products being tested. Results: Comparative analysis of the products revealed marked differences regardingin vitrorelease of the active principle (one product failing this important quality parameter). All the products tested here complied with the official specifications for identifying and assaying the active principle, dosage unit uniformity and the disintegration test. Regarding dissolution kinetics, differences were found between formulations as some products had poor dissolution efficiency (DE) and dissolved very slowly despite complying with the Q30specification. Conclusions: 11 products complied with USP33-NF28specifications (guidelines on specifications for impurities in antibiotics). This work has made a valuable contribution towards establishing these products’ bioequivalence in the near future regarding national policy.

Síndrome de Stevens-Johnson: presentación de un caso / Stevens-Johnson syndrome: a case presentation

El Síndrome de Stevens-Johnson es una enfermedad inflamatoria aguda, caracterizada por un eritema multiforme vesiculobuloso de la piel y otros órganos, se califica como la etapa inicial de una reacción dérmica cuya presentación más severa es la necrólisis epidérmica tóxica. La causa de esta enfermedad está ligada al uso de algunos fármacos en un 60 %, además de causas infecciosas y algunos factores genéticos predisponentes. La ciprofloxacino produce el síndrome en una frecuencia menor de uno en diez mil. Caso Clínico: se presenta el caso de una paciente de 69 años de edad con diagnóstico de Amigdalitis, recibió tratamiento con ciprofloxacina tabletas, a las veinticuatro horas de evolución, desarrolló un síndrome de Stevens-Johnson en forma muy severa con manifestaciones cutáneas, oculares y de la mucosa oral, que evolucionó a una necrólisis epidérmica tóxica, se acompañó de otras complicaciones y tuvo un desenlace fatal. Discusión: el Síndrome de Stevens-Johnson y la necrólisis epidérmica tóxica pueden presentarse con una erupción morbiliforme que puede evolucionar a necrosis de piel, comprometer el tubo digestivo, la tráquea, los bronquios, el tracto urinario, la vagina y las conjuntivas. En los casos graves pueden aparecer complicaciones como lesiones oculares persistentes, neumonía, estenosis esofágica, insuficiencia renal aguda, insuficiencia hepática, trastornos hematológicos, pérdidas masivas de fluidos por vía transepidérmica y sepsis, esta última constituye la causa principal de muerte.

Stevens-Johnson syndrome is an acute inflammatory disease, characterized by an erythema multiforme bullosum of the skin and other organs; it is considered the initial stage of a dermic reaction whose severest presentation is toxic epidermal necrolysis. Its cause is linked to the use of some drugs in a 60 %, as well as infectious causes and some genetic predisposing factors. Clinical case: a 69 years old woman with diagnosis of tonsillitis who received treatment with ciprofloxacin, to the twenty four hours of evolution the patient evolved a severe Stevens-Johnson syndrome with skin, ocular and oral mucosa manifestations that evolved to a toxic epidermal necrolysis, accompanied by other complications and had a fatal outcome. Discussion: Stevens-Johnson syndrome and toxic epidermal necrolysis may appeared with a morbilliform eruption that may develop to a necrosis of the skin, affecting digestive tube, trachea, the bronchi, urinary tract, vagina and conjunctivas. In the critical cases may appear complications like persistent ocular injuries, pneumonia, esophageal stenosis, chronic renal insufficiency, hepatic insufficiency, hematological disorders, massive losses of fluids by trans-epidermal via and sepsis, the last one constitute the main cause of death.

A influência do laboratório no tratamento da ceratite infecciosa / The influence of the laboratory in the treatment of the infectious keratitis

OBJETIVO: Avaliar a resposta terapêutica das ceratites infecciosas e sua correlação com o resultado laboratorial. MÉTODOS: Foram estudados 62 casos retrospectivamente de ceratite infecciosa de moderada à grave, atendidos no Hospitaldo Servidor Público Estadual de São Paulo no período de janeiro de 2000 a dezembro de 2006. Foi avaliada a resposta ao tratamento tópico com colírios antibióticos (Cefalotina 50mg/ml e Gentamicina 14mg/ml ou Ciprofloxacino 0,3 por cento), verificando-se a necessidade de modificação da terapêutica inicial de acordo com a evolução clínica e correlação com os testes microbiológicos pré-tratamento. RESULTADOS: Observou-se que 21 culturas (33,9 por cento) foram positivas e 41 (66,1 por cento) foram negativas. Houve crescimento de fungo em uma amostra (1,6 por cento). Em apenas dois casos (3,5 por cento) houve correlação do exame bacterioscópico com o da cultura. Em 5 casos (8,1 por cento) houve necessidade de modificação da medicação devido à piora clínica e 91,9 por cento dos pacientes cursaram com cura do processo infeccioso com o tratamento inicial instituído. CONCLUSÃO: O uso tópico de antibióticos fortificados ou quinolonas foi eficaz no tratamento das ceratites de provável etiologia infecciosa com culturas positivas e negativas.

PURPOSE: To evaluate the initial treatment of infectious keratitis, evolution and their correlation with laboratory tests. METHODS: 62 cases of infectious corneal ulcers seen in the Hospital do Servidor Público Estadual - São Paulo underwent Gramstaining and culture for bacterial and fungus. Treatment with fortified Cefalotine (50mg/ml) and Gentamicin (14mg/ml) or fluoroquinolone 0,3 percent was started. RESULTS: 21 cultures (33,9 percent) were positive for bacterial infection and 41 (66,1 percent) showed no growth. Just one case was positive for fungus(1,61 percent). In 2 cases (3,5 percent) the Gram staining showed correlation with the culture. Five cases (8,8 percent) did not respond to the initial treatment and had the medications changed and 91,9 percent responded to the initial clinical treatment. CONCLUSION: Ours results showed that combination of fortified eye drops or quinolones was efficient to treat infectious corneal ulcers with positive or negative cultures.

Uso y abuso del ciprofloxacino / Ciprofloxacin use and overuse

Las quinolonas son antibacterianos eficaces contra gérmenes gramnegativos y especialmente útiles para eliminar infecciones de las vías urinarias u otras localizaciones, así como también para tratar a pacientes con enfermedades de transmisión sexual. Al respecto se realizó un estudio sobre el uso y abuso del ciprofloxacino, por constituir un antimicrobiano comúnmente utilizado de forma inadecuada e indiscriminada.

Quinolones are effective antibacterials against gram-negative germs. In addition, they are especially useful to eliminate infections of the urine ducts and other regions, as well as to treat patients with sexually transmitted diseases. A study about the ciprofloxacin use and overuse was carried out because it is an antimicrobial which is commonly used in an inappropriately and indiscriminately way.

Depósitos corneales de ciprofloxacino / Corneal deposits of ciprofloxacin

Las fluoroquinolonas son ampliamente utilizadas para el tratamiento de infecciones oculares bacterianas, ya que tienen actividad tanto para grampositivos, como para gramnegativos. Son fármacos seguros, pero se han descrito depósitos blancos cristalinianos en pacientes con administración frecuente y prolongada;en la mayoría de los casos, ellos resuelven de forma lenta al interrumpir el tratamiento. Si esto no ocurre, los depósitos se deben desbridar. Se ilustran 3 casos operados de catarata que llevaron tratamiento con ciprofloxacino en el posoperatorio, en los cuales se presentaron depósitos corneales y aunque disminuyó la agudeza visual, esta se recuperó después de la queratectomía

Fluoroquinolones are broadly used for the treatment of bacterial ocular infections, since they can act upon both grampositive and gramnegative bacteria. They are safe drugs, but white corneal deposits have been described in patients who frequently take this drug for a long period of time. In most of the cases, the deposits disappear slowly after the treatment is interrupted. If this does not happen, the deposits should be eliminated. Three cases operated on from cataract were presented, who had been taken ciprofloxacin in the postoperative stage and had corneal deposits. Although their visual acuity decreased, it recovered after keratectomy

Meningoencefalitis a salmonella: presentación de casos / Meningoencephalitis to Salmonella: presentation of cases

Se presentan tres pacientes con el diagnóstico de meningoencefalitis a Salmonella (D no typhi en dos y C2 en uno) ingresados en la Unidad de Terapia Intensiva de nuestro hospital desde 1989 a 2006. La evolución de los infectados con el tipo D no typhi fue más severa, presentando uno de los pacientes osteomielitis de tercio inferior del húmero al mismo germen luego de 14 días de tratamiento con cefotaxima y otro con recaída de la meningoencefalitis luego de 21 días de tratamiento con cefotaxima y ampicillín. Al igual que otros autores observamos una evolución más agresiva de la infección en estos enfermos comparados con otras meningoencefalitis bacterianas y se recomienda tratamiento con cefalosporina de tercera generación al menos por 4 semanas sola o en asociación con ciprofloxacina.

We present three inpatients with the diagnosis of meningoencephalitis to Salmonella (Non-typhi D in two and C2 in one) attended in the Intensive Care Unit of our hospital from 1989 to 2006. The evolution of the patients infected with the kind non-typhi D was more severe; one of the patients presented osteomyelitis of the lower third of the humerus to the same germen after a 14-days treatment with cefotaxime, and other had a relapse of the meningoencephalitis after 21 days of treatment with cefotaxime and ampicillin. Like other authors, we observed a more aggressive evolution of the infection in these patients in comparison with other bacterial meningoencephalitis, and recommend the treatment with third generation cephalosporin alone at least during 4 weeks or in association with ciprofloxacin.

Resistencia antimicrobiana en la infección urinaria por Escherichia coli adquirida en la comunidad: ¿cuál antibiótico voy a usar? / Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections: what antimicrobial to use?

OBJETIVO: Determinar la resistencia del uropatógeno comunitario más frecuente, Escherichia coli, a diversos antimicrobianos y deducir opciones de manejo empírico. MATERIAL Y MÉTODOS: Del 14 de julio de 2005 al 13 julio de 2006 se estudiaron cepas de Escherichia coli aisladas de urocultivos de pacientes que asistieron a la consulta externa de la Clínica Nova y del Hospital San José, en Monterrey, Nuevo León, México. Se identificó la bacteria y se determinó susceptibilidad a antibióticos mediante método automatizado. Se compararon los resultados entre las dos instituciones y la frecuencia de resistencia a antimicrobianos entre mujeres de entre 15 a 50 años de edad y > 50. RESULTADOS: Se analizaron 652 urocultivos: 303 (46.5 por ciento) de Clínica Nova y 349 (53.5 por ciento) del Hospital San José. Las cepas aisladas fueron resistentes a ampicilina, en 67.2 por ciento; a trimetoprim-sulfametoxazol, en 59.2 por ciento; a cefazolina, en 35.6 por ciento, y a ciprofloxacino, en 24.7 por ciento. CONCLUSIONES: La resistencia a trimetoprim-sulfametoxazol y ciprofloxacino, considerados de elección en el manejo empírico de las infecciones de vías urinarias adquiridas en la comunidad, es alta. Las opciones de manejo son pocas.

OBJECTIVE: Determine antibiotic resistance of community-acquired uropathogen Escherichia coli and infer therapeutic options. MATERIAL AND METHODS: E. coli strains isolated from urine during a one-year period were studied. Identification and susceptibility tests were performed. RESULTS: A total of 652 isolates were included from patients in two institutions, a healthcare clinic 303 (46.5 percent) and a hospital 349 ( 53.5 percent). The antimicrobials with higher resistance rates were ampicillin 67.2 percent, trimethoprim-sulfametoxazole 59.2 percent, cefazolin 35.6 percent and ciprofloxacin 24.7 percent. CONCLUSIONS: Resistance to trimethoprim-sulfamethoxazole and ciprofloxacin used for empiric treatment in community urinary infections is high, and there are few available treatment options.

Influência da ciprofloxacina na consolidação óssea de fraturas de fêmur em ratos / Influence of ciprofloxacin on femoral fractures healing in rats

OBJETIVO: Apresentar um estudo experimental sobre o efeito da ciprofloxacina na resistência do calo ósseo de fraturas padronizadas de fêmures de ratos. MÉTODOS: Os ratos foram separados em dois grupos de oito animais: o grupo estudo (cipro) e o grupo controle. Os animais foram submetidos à fixação dos fêmures esquerdos com fio metálico intramedular e à confecção de fraturas padronizadas no mesmo osso. O grupo estudo recebeu ciprofloxacina e o grupo controle soro fisiológico durante seis semanas. Após este período, realizou-se estudo radiográfico controle e ensaio biomecânico de três pontos para obtenção da força de flexão mensurada em Newtons. RESULTADOS: As radiografias e a análise macroscópica demonstraram consolidação óssea em todas as fraturas. Foram comparados os resultados encontrados no estudo biomecânico entre os dois grupos, sendo que o grupo cipro apresentou resistência à força de flexão média 71,11 e o grupo controle, força de flexão média 74,78, não apresentando significância estatística (p = 0,601, test t). CONCLUSÃO: Não houve diferença estatística significante na resistência do calo ósseo de fraturas padronizadas de fêmur de ratos após o uso de ciprofloxacina em relação ao grupo controle.

OBJECTIVE: To present an experimental study about the effects of ciprofloxacin on the bone callus strength on femoral fractures in rats. METHODS: The animals were divided in two groups of 8 rats each: the group study (cipro) and the control group. The animals were fixed with an intramedullary nail and submitted to a standardized femoral fracture. The group study was treated with ciprofloxacin and the control group with saline solution for six weeks. After that period, the femurs were analyzed using X-ray images and biomechanical three-point test, which measured the flexion strength in Newtons. RESULTS: The X-ray images and the macroscopic analysis showed that all fractures healed. The results found in the biomechanical study between the two groups were compared, and the cipro group presented a mean resistance to flexion force of 71.11 and the contol group, mean flexion force of 74,78. There was no statistically significant difference (p = 0.601, t-test). CONCLUSION: The results from the biomechanical tests performed on femoral fractures in rats receiving ciprofloxacin revealed no statistical significance from measures of callus flexion strength when compared to the control group.

Flora bacteriana conjuntival após uso tópico de ciprofloxacino e gatifloxacino em cirurgia de catarata / Conjunctival bacterial flora after topical use of ciprofloxacin and gatifloxacin in cataract surgery

OBJETIVO: Avaliar alterações da flora conjuntival após uso dos colírios de ciprofloxacino e gatifloxacino 0,3 por cento na profilaxia dos pacientes submetidos à facectomia. MÉTODOS: Quarenta pacientes submetidos a facectomia foram alocados em dois grupos, conforme o colírio antibiótico utilizado: Grupo A: ciprofloxacino 0,3 por cento e Grupo B: gatifloxacino 0,3 por cento. Os pacientes usaram os colírios 1 hora antes da cirurgia e nos primeiros 14 dias pós-operatórios. Foi coletado material da conjuntiva em cinco momentos: 1 hora antes da cirurgia, sem medicações tópicas (t0); imediatamente antes da aplicação de iodopovidona (PVPI) (t1), antes do início da cirurgia, após iodopovidona (t2), 14 dias após a cirurgia (t3) e 28 dias após a cirurgia (t4). RESULTADOS: O uso de antibióticos no pré-operatório diminuiu a positividade das culturas anteriores ao uso do iodopovidona em ambos os grupos; no Grupo A esta redução não alcançou significância estatística (Grupo A - p=0,07 e Grupo B - p=0,04). A positividade das culturas foi reduzida nos dois grupos após aplicação de iodopovidona e 14 dias após a cirurgia (p<0,05). Em t4 a freqüência do Staphylococcus coagulase-negativo foi menor no grupo A quando comparado ao grupo B (p<0,05) e a sensibilidade ao ciprofloxacino em relação a t0 foi menor em todos grupos. CONCLUSÃO: O colírio de gatifloxacino aplicado 1 hora antes da cirurgia reduziu significantemente a positividade das culturas. Ambos antibióticos promoveram redução da flora quando administrados no pós-operatório.

PURPOSE: To evaluate alterations of the conjunctival flora after the use of 0.3 percent ciprofloxacin and gatifloxacin in the prophylaxis of patients undergoing cataract surgery. METHODS: 40 patients undergoing cataract surgery were distributed into two groups according to the use of antibiotic eye drops: Group A: 0.3 percent ciprofloxacin and Group B: 0.3 percent gatifloxacin. Both groups used antibiotic eye drops 1 hour before surgery and 14 days after surgery. Conjunctival material was collected at 5 time points: 1 hour before surgery, without any topical medication (t0); immediately before the application of povidone-iodine (PVPI) (t1), before the beginning of surgery, after povidone-iodine (t2), 14 days (t3) and 28 days after surgery (t4). RESULTS: Preoperative antibiotics reduced the positivity of the cultures before the use of PVPI in both groups, although in Group A this reduction was not significant (Group A - p=0.07 and Group B - p=0.04). The number of positive cultures was reduced in all groups after the use of povidone-iodine and on the 14th postoperative day (p<0.05). In t4 there was a reduction in the frequency of coagulase-negative Staphylococcus in Group A compared with Group B (p<0.05); the susceptibility to ciprofloxacin was also reduced in all groups, when compared with t0. CONCLUSIONS: Gatifloxacin eye drops applied one hour before surgery significantly reduced the number of positive conjunctival cultures. Both antibiotics reduced the conjunctival flora when administered in the postoperative period.

Endocarditis batteriana por actinobacillus actinomycetemcomitans: reporte de un caso / Bacterial endocartitis by actinobacillus actinomycetemcomitans: a case report

Se presenta un caso de endocarditis bacteriana, niño de seis años ingresado en el Hospital Pediátrico Provincial Docente ‘’Dr. Eduardo Agramonte Piña’’ en el mes de enero de 2006, con una sintomatología que puede inferir la presencia sospechosa de dengue. Se potenciaron exámenes que permitieron descartar esta enfermedad. En el primer hemocultivo realizado se aisló un Actinobacillus actinomycetemcomitans, este microorganismo es un cocobacilo gram negativo, anaerobio facultativo, inmóvil, no formador de esporas que fermenta carbohidratos sin producción de gas, forma parte de la flora normal de la boca humana y es muy sensible a los antimicrobianos, resolvió con el tratamiento antibacteriano impuesto, de ceftriaxona y ciprofloxacina que fue sustituido por gentamicina y ampicillín.

A case of bacterial endocarditis is presented, a boy of six years entered at “Dr. Eduardo Agramonte Piña” Educational Provincial Paediatric Hospital on January 2006, with a symptomatology that can infer the suspicious presence of dengue. Exams were promoted that permitted to reject this illness. In the first hemoculture carried out, an Actinobacillus actinomycetemcomitans was isolated, this microorganism is a gram negative coccobacillus, facultative anaerobe, motionless, not spores former that ferments carbohydrates without gas production, it is a part of the normal flora of the human mouth and is very sensitive to the antimicrobial, the patient solved with the antibacterial treatment, of ceftriaxone and ciprofloxacin that was substituted by gentamyicin and ampicillin.

Evaluación prospectiva de la combinación colirio-ungüento de ciprofloxacino-dexametasona y tobramicina-dexametasona en cirugía de catarata / Prospective evaluation of eye drops and ointments of ciprofloxacin/dexamethasone versus tobramycin/dexamethasone combinations in ocular surgery

El uso profiláctico de antibióticos y antiinflamatorios post cirugía oftálmica es una práctica común. La tobramicina es aminoglicósido con espectro de gram negativos y alguns gram positivos. Ciprofloxacino tiene un mayor espectro. Objetivo: Comparar la eficacia y seguridad de la combinación colirio y ungüento de cirpofloxacino/dexametasona versus tobramicina/dexametasona. Pacientes y métodos: Se estudio en forma randomizada y doble ciego, 64 pacientes durante 15 días. Se realizaron 3 controles donde se registró agudeza visual, presión intraocular y una escala subjetiva y objetiva. Resultados: 60 pacientes completaron el estudio. El prurito fue menor en el grupo tratado con ciprofloxacino (0.26 v/s 0.47; p<0,05). Conclusiones: El estudio demostró eficacia y seguridad antibiótica equivalente entre ambas combinaciones. Considerando el mayor espectro antibacteriano de ciprofloxacino y la menor incidencia de prurito se plantea que el uso de esta combinación en pacientes post cirugía de catarata entregaría una protección antibiótica segura y con espectro más amplio.

The prohylactic use of antibiotics and anti-inflammatories drugs is a common practice in ophthalmic surgery. Tobramycin is an aminoglycoside with gram negative spectrum, covering some gram positive bacteria. Ciprofloxacin has a broader spectrum of effectivity. Purpose: To compare effectiveness and safety of eye drops and ointments of ciprofloxacim/dexamethasone versus tobramysin/dexamethasone combinations. Patients and methods: Random and doubled masked study, performed in 64 patients who had cataract surgery. In a 15 days follow up, the effectiveness of both antibiotic combinations were tested. Visual acuity, intraocular pressure, objective and subjective scale were performed. Results: 60 patients (93.4 percent) completed the follow up. Itching presented a significant difference between both groups, being lower in the ciprofloxacin/dexamethasone combination (0.26 vs 0.47. p<0.05). Conclusions: The study shows an equivalent effectiveness and safety of both antibiotic combinations. Considering the broader spectrum of ciprofloxacin and the lower frequency of itchness, ciprofloxacin/dexamethasone combination seems to be a good choice for post operative treatment in cataract surgery.

Marcação do ciprofloxacino com tecnécio-99m

Mesmo com o desenvolvimento tecnológico, a localização de processos infecciosos, em pacientes com febre de origem desconhecida, continua sendo um desafio para a Medicina. Com o objetivo de fazer o diagnóstico diferencial entre inflamação e infecção, através do método cintilográfico, realizamos a marcação do ciprofoxacino com Tecnécio-99m. A marcação do ciprofloxacino foi realizada tendo como agente redutor o cloreto estanoso bi-hidratado (SnCh2.2.H20). Foram empregados na marcação, 2mg de ciprofloxacino produzido pela BayerR, 400mg de SnCh2.2.H20 (Sigma Chemical Co.) e 185 MBq de Tecnécio-99m sob à forma de pertecnetato (99mTc04) em volume de 300uL. A marcação foi feita a 100ºC durante 1O min e à temperatura ambiente no mesmo tempo. A solução obtida foi filtrada em Millipore de 0,22mm A eficiência de marcação foi verificada por cromatografia ascendente em papel Whatman nº 1, em papel Whatman n°3MM, cromatografia em camada fina e cromatografia por exclusão (Bio-Gel PIO), sendo que para o papel Whatman nº1 foi de 97,3 % ± 1,6; em papel Whatman nº3MM 96,8 ± 2,3, em cromatografia de camada fina 96,6 ± 2,1 e para confirmação destes resultados utiliza-se a cromatografia por exclusão com Bio-Gel P 10; as moléculas marcadas foram eluídas primeiro, seguidas das moléculas de Tecnécio-99m enquanto os colóides permaneceram aderidos à coluna. A marcação do ciprofloxacino com 99mTc não alterou a biodistribuição biológica do ciprof1oxacino, apresentando, em coelhos, alta concentração renal, moderada captação em fígado e baço e nenhuma captação em medula óssea. Os nossos resultados de eficiência de marcação e biodistribuição foram compatíveis com a literatura

Even with technologica1 development, the localization of infectious processes, in patients with fever of unknown origin, continues to be a challenge for Medicine. With the aim of rnaking a differential diagnosis between inflammation and infection, by means of a scintigraphic method, we labeled ciprofloxacin with Technetium99m. The labeling of ciprofloxacin was carried out using stannous chloride dihydrate (SnCh2.2.H20) as a reducing agent. In the labeling 2mg de ciprofloxacin manufactured by BayerR were used, 400mg de SnCh2.2.H20 (Sigma Chemical Co.) and 185MBq of Teclmetium-99m in the form of pertechnetate (99mTc04) in 300mL of volume. The labeling was carried out at 100°C for 10 minutes and at the ambient temperature during the same time. The solution obtained was filtered in Millipore of 0,22mm. The efficiency of the labeling was verified by ascendant chromatography on Whatman nº1 paper which was 97,3 % ±1,6; and on Whatman nº3MM paper with 96,8% ±2,3; in thin 1ayer chromatography with 96,6% ±2,1 and for confirmation of these results chromatography by exc1usion (Bio-Gel P 10) was used. The mo1ecu1es 1abe1ed were e1uted first, fol1owed by the rno1ecu1es of Technetium-99m while the colloids remained attached to the column. The biodistribution was carried out in New Zea1and white rabbits, confirming the bio10gica1 behavior of ciproflaxin labeled with Technetium-99m, showing a high uptake, in the kidneys moderate uptake in the 1iver and sp1een and no bone marrow uptake. These resu1ts for the efficiency of1abeling and biodistribution were compatible with that of the literature